Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes

NCT01511198 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01511198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01511198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2001
Completion date
October 31, 2001
Enrollment
223 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2